Where does Athenex, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Athenex, Inc. ranks #20,780 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Athenex, Inc. hold?

Athenex, Inc. holds 13 US utility patents granted between 2017 and 2023, spanning 5 technology areas.

What is Athenex, Inc.'s Innovation Score?

Athenex, Inc. has an Innovation Score of 27.8 out of 100 (top 75% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Athenex, Inc.'s patent grant rate increasing or decreasing?

Athenex, Inc.'s recent grant velocity is -56% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Athenex, Inc.'s patents?

Athenex, Inc.'s patents average 16.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Athenex, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Athenex, Inc.

Q: What technology areas does Athenex, Inc. focus on?

Athenex, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 13 patents. Grants appear in 5 CPC subclasses total.

USPTO PatentsView assignee record - 13 granted patents across 5 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Athenex ranks #20,780 of 50,000 tracked US assignees by granted-patent volume, with 13 patents across 5 technology areas.

#20,780
of 50,000 US assignees by volume: Top 75%
by Innovation Score (27.8/100): 16.4
avg claims per patent: -56%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R20780 · US Corporation #20,780 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 13 grants
MID-PACK #20,780/50,000
PHOTO-FINISH Ascent Solar
CPC-NARROW A61P · 5 areas
INNOV-THIN 27.8/100
CLAIMS-RICH 16.4 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -56% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ascent Solar Technologies, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Athenex · this assignee

28
3D Lighting Innovati… · lowest

7

What this shows Athenex's Innovation Score is 27.8/100 (top 75% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Athenex's grants concentrate

Athenex, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2020. By volume, Athenex sits between Ascent Solar Technologies, Inc. and Autotech Engineering Deutschland Gmbh.

Ascent Solar

13
Ashland Licensing…

13
Astrazeneca Pharm…

13
Asymptote

13
Atlantic Health S…

13
Aurora Spine

13
Austin Engineering

13
Autotech Engineer…

13
Athenex ◀

13

What this shows Athenex holds 13 patents at rank #20,787, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Athenex

By rank, the assignees closest to #20,787 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Athenex's primary technology class.

Athenex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 Top 75% higher than 25% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Athenex, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	3	23.1%
2018	2	15.4%
2019	4	30.8%
2020	1	7.7%
2021	2	15.4%
2023	1	7.7%

Which technologies does Athenex, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 13

C07D - HETEROCYCLIC COMPOUNDS 12

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 7

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 6

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 2

Top 5 of 5 technology areas

Where it ranks

Overall rank by patents

#20,780

of 50,000 tracked assignees

Innovation Score

27.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.